Bicycle Therapeutics Company Insiders
BCYC Stock | USD 8.71 0.34 4.06% |
Bicycle Therapeutics employs about 305 people. The company is managed by 17 executives with a total tenure of roughly 712 years, averaging almost 41.0 years of service per executive, having 17.94 employees per reported executive. Evaluation of Bicycle Therapeutics' management performance can provide insight into the firm performance.
Bicycle Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2169) % which means that it has lost $0.2169 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3707) %, meaning that it created substantial loss on money invested by shareholders. Bicycle Therapeutics' management efficiency ratios could be used to measure how well Bicycle Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Bicycle Therapeutics Workforce Comparison
Bicycle Therapeutics is rated fourth in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,551. Bicycle Therapeutics retains roughly 305 in number of employees claiming about 12% of equities under Health Care industry.
Bicycle Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bicycle Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bicycle Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bicycle Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Travis Thompson over two weeks ago Disposition of 100 shares by Travis Thompson of Bicycle Therapeutics at 7.44 subject to Rule 16b-3 | ||
Lee Kevin over a month ago Disposition of 3432 shares by Lee Kevin of Bicycle Therapeutics at 7.48 subject to Rule 16b-3 | ||
Baker Bros. Advisors Lp over two months ago Acquisition by Baker Bros. Advisors Lp of 5573 shares of Bicycle Therapeutics at 13.6288 subject to Rule 16b-3 | ||
Skynner Michael over two months ago Disposition of 936 shares by Skynner Michael of Bicycle Therapeutics at 14.75 subject to Rule 16b-3 | ||
Travis Thompson over three months ago Disposition of 109 shares by Travis Thompson of Bicycle Therapeutics at 7.48 subject to Rule 16b-3 | ||
Westin Eric over three months ago Insider Trading | ||
Travis Thompson over three months ago Acquisition by Travis Thompson of 43500 shares of Bicycle Therapeutics at 14.0 subject to Rule 16b-3 | ||
Lee Kevin over six months ago Disposition of 9038 shares by Lee Kevin of Bicycle Therapeutics at 14.09 subject to Rule 16b-3 |
Bicycle Therapeutics Notable Stakeholders
A Bicycle Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bicycle Therapeutics often face trade-offs trying to please all of them. Bicycle Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bicycle Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Lee MBA | President | Profile | |
Travis Thompson | Chief VP | Profile | |
Kevin MBA | CEO Director | Profile | |
CBE FMedsci | NonEx CoFounder | Profile | |
Christian Heinis | Scientific Founder | Profile | |
Stephanie Yao | Senior Communications | Profile | |
Phil Jeffrey | Senior Development | Profile | |
Alistair Milnes | Chief Officer | Profile | |
Gillian Langford | Head Management | Profile | |
Alethia Young | Chief Officer | Profile | |
David CFA | Senior Communications | Profile | |
Nicholas Keen | Chief Officer | Profile | |
Dr B | Chief Officer | Profile | |
Zafar Qadir | General Counsel | Profile | |
Pr Hannay | Chief Officer | Profile | |
MBA MBA | Pres CFO | Profile | |
Santiago MD | Chief Officer | Profile |
About Bicycle Therapeutics Management Performance
The success or failure of an entity such as Bicycle Therapeutics often depends on how effective the management is. Bicycle Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bicycle management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bicycle management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. Bicycle Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 119 people.
Please note, the presentation of Bicycle Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bicycle Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Bicycle Therapeutics' management manipulating its earnings.
Bicycle Therapeutics Workforce Analysis
Traditionally, organizations such as Bicycle Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bicycle Therapeutics within its industry.Bicycle Therapeutics Manpower Efficiency
Return on Bicycle Therapeutics Manpower
Revenue Per Employee | 115.7K | |
Revenue Per Executive | 2.1M | |
Net Loss Per Employee | 554.2K | |
Net Loss Per Executive | 9.9M | |
Working Capital Per Employee | 2.8M | |
Working Capital Per Executive | 50.7M |
Complementary Tools for Bicycle Stock analysis
When running Bicycle Therapeutics' price analysis, check to measure Bicycle Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicycle Therapeutics is operating at the current time. Most of Bicycle Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicycle Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicycle Therapeutics' price. Additionally, you may evaluate how the addition of Bicycle Therapeutics to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |